ArticleCureus2026
Sustained Remission in a Patient With Depression, Chronic Insomnia, and Ischemic Heart Disease Using a Combination of Agomelatine and Mirtazapine: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Agomelatine and mirtazapine are antidepressants with complementary pharmacological profiles. However, this combination is rarely reported in clinical practice. We report a case of a 54-year-old man with ischemic heart disease, diabetes, and hypothyroidism, who achieved early full remission of major depressive disorder and chronic insomnia following treatment with agomelatine and mirtazapine. By the four-week follow-up, the patient reported sleeping 8-9 hours/night with normalized mood and cognitive function. He sustained full remission for over three months, with no adverse effects. Serial lab investigations and ECGs remained stable throughout. No arrhythmic events or QTc prolongation were observed during follow-up. While not commonly reported together in routine care, the combination was well tolerated and appeared to support both mood improvement and sleep restoration, without notable side effects, despite the presence of multiple cardiovascular and metabolic comorbidities. This case adds to the expanding literature and suggests that this combination may be a useful off-label option for select patients with depression and insomnia who are at risk of cardiovascular or metabolic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.